Current trends in biobanking for rare diseases: a review [Corrigendum]

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Journal of Biorepository Science for Applied Medicine 2014:2 49–61 Journal of Biorepository Science for Applied Medicine Dovepress

[1]  B. Knoppers,et al.  International Charter of principles for sharing bio-specimens and data , 2016, European Journal of Human Genetics.

[2]  Lucia Monaco,et al.  The Challenge for a European Network of Biobanks for Rare Diseases Taken up by RD-Connect , 2015, Pathobiology.

[3]  M. Hansson,et al.  Incidental findings: the time is not yet ripe for a policy for biobanks , 2014, European Journal of Human Genetics.

[4]  F. Bianchi,et al.  European Recommendations for Primary Prevention of Congenital Anomalies: A Joined Effort of EUROCAT and EUROPLAN Projects to Facilitate Inclusion of This Topic in the National Rare Disease Plans , 2014, Public Health Genomics.

[5]  Bahram Valamehr,et al.  Myogenic Differentiation of Muscular Dystrophy‐Specific Induced Pluripotent Stem Cells for Use in Drug Discovery , 2014, Stem cells translational medicine.

[6]  Paul Wicks,et al.  Subjects no more: what happens when trial participants realize they hold the power? , 2014, BMJ : British Medical Journal.

[7]  A. Lisitsa,et al.  Profiling proteoforms: promising follow-up of proteomics for biomarker discovery , 2014, Expert review of proteomics.

[8]  Lauren B Vensand,et al.  Generation of iPSC lines from archived non-cryoprotected biobanked dura mater , 2014, Acta neuropathologica communications.

[9]  Christophe Béroud,et al.  Dispelling myths about rare disease registry system development , 2013, Source Code for Biology and Medicine.

[10]  C. Angelini,et al.  Telethon Network of Genetic Biobanks: a key service for diagnosis and research on rare diseases , 2013, Orphanet Journal of Rare Diseases.

[11]  David A Mackey,et al.  Establishment and evolution of the Australian Inherited Retinal Disease Register and DNA Bank , 2013, Clinical & experimental ophthalmology.

[12]  R. Moxley,et al.  Diagnostic odyssey of patients with myotonic dystrophy , 2013, Journal of Neurology.

[13]  Matthew D. Shirley,et al.  Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. , 2013, The New England journal of medicine.

[14]  R. Chadwick,et al.  Patients would benefit from simplified ethical review and consent procedure. , 2013, The Lancet. Oncology.

[15]  Kelly Edwards,et al.  The haystack is made of needles. , 2013, Genetic testing and molecular biomarkers.

[16]  K. Steinsbekk,et al.  Broad consent versus dynamic consent in biobank research: Is passive participation an ethical problem? , 2013, European Journal of Human Genetics.

[17]  Emilie Devries-Seguin.  Population studies: return of research results and incidental findings Policy statement , 2013 .

[18]  K. Moodley,et al.  Challenges in biobank governance in , 2013 .

[19]  A. Koeppen,et al.  Relation of cytosolic iron excess to cardiomyopathy of Friedreich's ataxia. , 2012, The American journal of cardiology.

[20]  V. Mootha,et al.  Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions. , 2012, Brain : a journal of neurology.

[21]  Adam Hunter,et al.  A modular approach to disease registry design: Successful adoption of an internet‐based rare disease registry , 2012, Human mutation.

[22]  Where should we draw the line between quality of care and other ethical concerns related to medical registries and biobanks? , 2012, Theoretical medicine and bioethics.

[23]  Johann Eder,et al.  IT Solutions for Privacy Protection in Biobanking , 2012, Public Health Genomics.

[24]  F. Dhombres,et al.  Representation of rare diseases in health information systems: The orphanet approach to serve a wide range of end users , 2012, Human mutation.

[25]  B. Knoppers,et al.  ELSI challenges and strategies of national biobank infrastructures , 2012 .

[26]  L. Santoro,et al.  Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. , 2012, American journal of human genetics.

[27]  Kelly Edwards,et al.  From patients to partners: participant-centric initiatives in biomedical research , 2012, Nature Reviews Genetics.

[28]  M. Hansson,et al.  Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases , 2012, Archives of Disease in Childhood.

[29]  Robert C. Green,et al.  Managing incidental findings and research results in genomic research involving biobanks and archived data sets , 2012, Genetics in Medicine.

[30]  Sampling Populations of Humans Across the World: ELSI Issues , 2012 .

[31]  Abstracts of the 6th European Conference on Rare Diseases and Orphan Products. Brussels, Belgium. May 23-25, 2012. , 2012, Orphanet journal of rare diseases.

[32]  G. Lauss,et al.  Biobank governance: heterogeneous modes of ordering and democratization , 2011, Journal of Community Genetics.

[33]  B. Keogh.  European biobanks forge cross-border ties. , 2011, Journal of the National Cancer Institute.

[34]  S. Eriksson,et al.  Biobank research: who benefits from individual consent? , 2011, BMJ : British Medical Journal.

[35]  M. Waldenberger,et al.  Comprehensive catalog of European biobanks , 2011, Nature Biotechnology.

[36]  H. Dawkins,et al.  Awakening Australia to Rare Diseases: Symposium report and preliminary outcomes , 2011, Orphanet journal of rare diseases.

[37]  M. Posada de la Paz,et al.  Proteomics of toxic oil syndrome in humans: Phenotype distribution in a population of patients. , 2011, Chemico-biological interactions.

[38]  C. Compton,et al.  Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. , 2011, Journal of the National Cancer Institute. Monographs.

[39]  Pierre Hainaut,et al.  Biobanking in a fast moving world: an international perspective. , 2011, Journal of the National Cancer Institute. Monographs.

[40]  G. Comi,et al.  Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  S. Eriksson,et al.  The risks and benefits of re-consent. , 2011, Science.

[42]  Sharon F Terry,et al.  Genetic Alliance Registry and BioBank: a novel disease advocacy-driven research solution. , 2011, Personalized medicine.

[43]  C. Angelini,et al.  Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency , 2011, Neurological research.

[44]  J. Vaught,et al.  Best practices for establishing a biobank. , 2011, Methods in molecular biology.

[45]  N. Bresolin,et al.  Clinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencing , 2011, BMC Medical Genetics.

[46]  R. Yeung,et al.  Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition. , 2010, The American journal of pathology.

[47]  Helen M. Moore,et al.  Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). , 2010, Contemporary clinical trials.

[48]  M. Hansson.  Need for a wider view of autonomy in epidemiological research , 2010, BMJ : British Medical Journal.

[49]  J. Sévigny,et al.  Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[50]  Hanns Lochmüller,et al.  Biobanking in rare disorders. , 2010, Advances in experimental medicine and biology.

[51]  W. Maurice.  Structuring Public Engagement for Effective Input in Policy Development on Human Tissue Biobanking , 2010 .

[52]  M. Hansson.  Taking the patient's side: the ethics of pharmacogenetics. , 2010, Personalized medicine.

[53]  Y. Zurynski,et al.  Call for a national plan for rare diseases , 2010, Journal of paediatrics and child health.

[54]  S. Antonarakis,et al.  The role of biobanking in rare diseases: European consensus expert group report. , 2009, Biopreservation and biobanking.

[55]  Alasdair Breckenridge,et al.  Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma , 2008, Nature Reviews Drug Discovery.

[56]  Jan-Eric Litton,et al.  Biobanking for Europe , 2007, Briefings Bioinform..

[57]  Kurt Zatloukal,et al.  Biobanks: transnational, European and global networks. , 2007, Briefings in functional genomics & proteomics.

[58]  A Berghold,et al.  The Genome Austria Tissue Bank (GATiB) , 2007, Pathobiology.

[59]  Sharon F. Terry,et al.  Science and society: Advocacy groups as research organizations: the PXE International example , 2007, Nature Reviews Genetics.

[60]  Philip M Baird,et al.  Large-Scale Repository Design , 2005 .